DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1640)

Attention-Deficit-Hyperactivity Disorder | Landscape & Forecast | Disease Landscape & Forecast

Attention-Deficit-Hyperactivity Disorder | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming December 2018

Market Outlook

Attention-deficit-hyperactivity disorder (ADHD) affects over 40 million people—children, adolescents, and adults—across the major pharmaceutical markets. The key treatment goals for both pediatric and adult ADHD include controlling the core symptoms of the condition—inattention and/or hyperactivity/impulsivity—as well improving patients’ overall functioning and quality of life. Psychostimulants are the predominant drug class prescribed for both pediatric and adult ADHD, though nonstimulant therapies serve as alternative or later-line options. Shortcomings in existing therapies, however, represent potential areas of opportunity for emerging therapies to be differentiated from competitors. Furthermore, recognition and diagnosis of adult ADHD continues to grow, particularly in the United States, but this population remains underdetected and undertreated, representing a sizable market opportunity.

QUESTIONS ANSWERED

  • What is the current state of treatment for pediatric and adult ADHD across the G7, and what needs are left unfulfilled by current ADHD therapies?
  • How has the entrance of generic competition to key drugs (e.g., Eli Lilly’s Strattera [atomoxetine]) modified the ADHD treatment landscape?
  • How have newer-to-market and brand-only agents (e.g., Shire’s Mydayis, Neos Therapeutics’ Adzenys ER) been incorporated into medical practice? What are physicians’ perception of these therapies?
  • What emerging therapies do ADHD thought leaders consider the most promising for pediatric ADHD and adult ADHD?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, EU5, Japan

Primary research: 17 country-specific interviews with thought-leading psychiatrists and ADHD experts

Supported by survey data collected for this and other DRG research

Epidemiology: Prevalence of ADHD by country, segmented by pediatric and adult ADHD

Forecast: 10-year, annualized, drug-level sales and patient share of key ADHD therapies through 2027, segmented by brands/generics and pediatric/adult ADHD.

Emerging therapies: Phase III/PR: 5 drugs. Phase II: 4 drugs. Coverage of select preclinical and Phase I products.

Coming soon
  • Pub Date: December 2018
  • Author(s): Joyce Spadafora, ALM

Request report

Recent reports: